Literature DB >> 19931251

Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice.

Corinne G Jolivalt1, Rosemarie Hurford, Corinne A Lee, Wilmar Dumaop, Edward Rockenstein, Eliezer Masliah.   

Abstract

A number of studies suggest an association between Alzheimer's disease (AD) and diabetes: AD patients show impaired insulin function, whereas cognitive deficits and increased risk of developing AD occur in diabetic patients. The reasons for the increased risk are not known. Recent studies of disturbances in the insulin-signaling pathway have revealed new perspectives on the links between AD and Type 1 diabetes with a particular focus on glycogen synthase-kinase-3 (GSK3). We have therefore characterized a mouse model of combined insulin-deficient diabetes and AD and find that diabetes exaggerated defects in the brain of APP transgenic mice. Mice with combined APP overexpression and diabetes showed a decreased insulin receptor activity and an increased GSK3beta activity. Concomitantly, tau phosphorylation and number of Abeta plaques, the two pathologic hallmarks of AD, were increased in the brain of diabetic-APP transgenic mice. Our results indicate that the pathologic features of AD are exaggerated in the brain of APP transgenic mice that have concurrent insulin-deficient diabetes, and underscore a possible mechanism of brain dysfunction common to AD and diabetes. Copyright (c) 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19931251      PMCID: PMC2864332          DOI: 10.1016/j.expneurol.2009.11.005

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  54 in total

1.  Alzheimer-like changes in protein kinase B and glycogen synthase kinase-3 in rat frontal cortex and hippocampus after damage to the insulin signalling pathway.

Authors:  Melita Salkovic-Petrisic; Florian Tribl; Manuela Schmidt; Siegfried Hoyer; Peter Riederer
Journal:  J Neurochem       Date:  2006-01-12       Impact factor: 5.372

2.  Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1-42).

Authors:  E Rockenstein; M Mallory; M Mante; A Sisk; E Masliaha
Journal:  J Neurosci Res       Date:  2001-11-15       Impact factor: 4.164

3.  Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains.

Authors:  A Pérez; L Morelli; J C Cresto; E M Castaño
Journal:  Neurochem Res       Date:  2000-02       Impact factor: 3.996

4.  Tau phosphorylation in transgenic mice expressing glycogen synthase kinase-3beta transgenes.

Authors:  J Brownlees; N G Irving; J P Brion; B J Gibb; U Wagner; J Woodgett; C C Miller
Journal:  Neuroreport       Date:  1997-10-20       Impact factor: 1.837

5.  Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging.

Authors:  Chris MacKnight; Kenneth Rockwood; Erin Awalt; Ian McDowell
Journal:  Dement Geriatr Cogn Disord       Date:  2002       Impact factor: 2.959

6.  Diabetes and Alzheimer's disease - is there a connection?

Authors:  Anders A F Sima; Zhen-Guo Li
Journal:  Rev Diabet Stud       Date:  2007-02-10

7.  Alzheimer-like changes in rat models of spontaneous diabetes.

Authors:  Zhen-guo Li; Weixian Zhang; Anders A F Sima
Journal:  Diabetes       Date:  2007-04-24       Impact factor: 9.461

8.  Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin.

Authors:  C G Jolivalt; C A Lee; K K Beiswenger; J L Smith; M Orlov; M A Torrance; E Masliah
Journal:  J Neurosci Res       Date:  2008-11-15       Impact factor: 4.164

9.  GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides.

Authors:  Christopher J Phiel; Christina A Wilson; Virginia M-Y Lee; Peter S Klein
Journal:  Nature       Date:  2003-05-22       Impact factor: 49.962

10.  DIABETIC ENCEPHALOPATHY. DIFFUSE AND FOCAL LESIONS OF THE BRAIN IN LONG-TERM DIABETES.

Authors:  E RESKE-NIELSEN; K LUNDBAEK
Journal:  Acta Neurol Scand Suppl       Date:  1963
View more
  66 in total

1.  Co-location of HDAC2 and insulin signaling components in the adult mouse hippocampus.

Authors:  Zhi-Gang Yao; Yu Liu; Ling Zhang; Lan Huang; Chun-Mei Ma; Yan-Feng Xu; Hua Zhu; Chuan Qin
Journal:  Cell Mol Neurobiol       Date:  2012-06-26       Impact factor: 5.046

2.  Intracerebroventricular streptozotocin exacerbates Alzheimer-like changes of 3xTg-AD mice.

Authors:  Yanxing Chen; Zhihou Liang; Zhu Tian; Julie Blanchard; Chun-Ling Dai; Sonia Chalbot; Khalid Iqbal; Fei Liu; Cheng-Xin Gong
Journal:  Mol Neurobiol       Date:  2013-08-31       Impact factor: 5.590

Review 3.  Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?

Authors:  Kawser Akter; Emily A Lanza; Stephen A Martin; Natalie Myronyuk; Melanie Rua; Robert B Raffa
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

Review 4.  Aβ oligomer-induced synapse degeneration in Alzheimer's disease.

Authors:  Kyle C Wilcox; Pascale N Lacor; Jason Pitt; William L Klein
Journal:  Cell Mol Neurobiol       Date:  2011-05-03       Impact factor: 5.046

5.  Diabetes exacerbates amyloid and neurovascular pathology in aging-accelerated mice.

Authors:  Antonio Currais; Marguerite Prior; David Lo; Corinne Jolivalt; David Schubert; Pamela Maher
Journal:  Aging Cell       Date:  2012-10-01       Impact factor: 9.304

6.  Synergistic exacerbation of mitochondrial and synaptic dysfunction and resultant learning and memory deficit in a mouse model of diabetic Alzheimer's disease.

Authors:  Yongfu Wang; Long Wu; Jianping Li; Du Fang; Changjia Zhong; John Xi Chen; Shirley ShiDu Yan
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

7.  Pioglitazone ameliorates memory deficits in streptozotocin-induced diabetic mice by reducing brain β-amyloid through PPARγ activation.

Authors:  Li-ping Liu; Tian-hua Yan; Li-ying Jiang; Wei Hu; Meng Hu; Chao Wang; Qian Zhang; Yan Long; Jiang-qing Wang; Yong-qi Li; Mei Hu; Hao Hong
Journal:  Acta Pharmacol Sin       Date:  2013-03-25       Impact factor: 6.150

8.  Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model.

Authors:  Xu Wang; Wei Zheng; Jing-Wei Xie; Tao Wang; Si-Ling Wang; Wei-Ping Teng; Zhan-You Wang
Journal:  Mol Neurodegener       Date:  2010-11-02       Impact factor: 14.195

9.  Protective effect of valproic acid in streptozotocin-induced sporadic Alzheimer's disease mouse model: possible involvement of the cholinergic system.

Authors:  Mirna Ezzat Sorial; Nesrine Salah El Dine El Sayed
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-02-10       Impact factor: 3.000

10.  Protection against the synaptic targeting and toxicity of Alzheimer's-associated Aβ oligomers by insulin mimetic chiro-inositols.

Authors:  Jason Pitt; Michael Thorner; David Brautigan; Joseph Larner; William L Klein
Journal:  FASEB J       Date:  2012-10-16       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.